Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1146027/full |
| _version_ | 1797869608195063808 |
|---|---|
| author | Joseph R. Berger Hans-Peter Hartung Hans-Peter Hartung Hans-Peter Hartung |
| author_facet | Joseph R. Berger Hans-Peter Hartung Hans-Peter Hartung Hans-Peter Hartung |
| author_sort | Joseph R. Berger |
| collection | DOAJ |
| first_indexed | 2024-04-10T00:15:18Z |
| format | Article |
| id | doaj.art-3aef3971c0b2443c947d685571be9582 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-10T00:15:18Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-3aef3971c0b2443c947d685571be95822023-03-16T05:28:30ZengFrontiers Media S.A.Frontiers in Neurology1664-22952023-03-011410.3389/fneur.2023.11460271146027Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapiesJoseph R. Berger0Hans-Peter Hartung1Hans-Peter Hartung2Hans-Peter Hartung3Department of Neurology, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, United StatesDepartment of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, GermanyBrain and Mind Center, University of Sydney, Sydney, NSW, AustraliaDepartment of Neurology, Palacky University, Olomouc, Czechiahttps://www.frontiersin.org/articles/10.3389/fneur.2023.1146027/fullprogressive multifocal leucoencephalopathy (PML)multiple sclerosisnatalizumabrisk factorsimmunogenetics |
| spellingShingle | Joseph R. Berger Hans-Peter Hartung Hans-Peter Hartung Hans-Peter Hartung Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies Frontiers in Neurology progressive multifocal leucoencephalopathy (PML) multiple sclerosis natalizumab risk factors immunogenetics |
| title | Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies |
| title_full | Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies |
| title_fullStr | Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies |
| title_full_unstemmed | Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies |
| title_short | Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies |
| title_sort | commentary progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies |
| topic | progressive multifocal leucoencephalopathy (PML) multiple sclerosis natalizumab risk factors immunogenetics |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2023.1146027/full |
| work_keys_str_mv | AT josephrberger commentaryprogressivemultifocalleukoencephalopathygeneticriskvariantsforpharmacovigilanceofimmunosuppressanttherapies AT hanspeterhartung commentaryprogressivemultifocalleukoencephalopathygeneticriskvariantsforpharmacovigilanceofimmunosuppressanttherapies AT hanspeterhartung commentaryprogressivemultifocalleukoencephalopathygeneticriskvariantsforpharmacovigilanceofimmunosuppressanttherapies AT hanspeterhartung commentaryprogressivemultifocalleukoencephalopathygeneticriskvariantsforpharmacovigilanceofimmunosuppressanttherapies |